Scarica l'app Stockscreener
0.4865
0.98%
-0.0048
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.4913
Aprire:
$0.5
Volume 24 ore:
44,455
Relative Volume:
0.34
Capitalizzazione di mercato:
$5.22M
Reddito:
-
Utile/perdita netta:
$-3.28M
Rapporto P/E:
-0.4675
EPS:
-1.0406
Flusso di cassa netto:
$-4.80M
1 W Prestazione:
-5.53%
1M Prestazione:
-19.05%
6M Prestazione:
-29.78%
1 anno Prestazione:
-47.90%
Intervallo 1D:
$0.4855
$0.5009
Intervallo di 1 settimana:
$0.4702
$0.5298
Portata 52W:
$0.4702
$1.51
Pharmacyte Biotech Inc Stock (PMCB) Company Profile
Nome
Pharmacyte Biotech Inc
Settore
Industria
Telefono
(917) 595.2850
Indirizzo
3960 HOWARD HUGHES PARKWAY, LAS VEGAS
Compare PMCB vs PSNYW, GOODO, SHMD, DWLD, QQQE
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| 2.24 | 0 | 0 | 0 | 0 | 0.00 | |
PSNYW
Polestar Automotive Holding Uk
|
5.00 | 394.14M | 2.07B | -1.42B | -1.37B | -0.6765 |
GOODO
Gladstone Commercial Corporation
|
20.92 | 372.90M | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
3.15 | 315.90M | 52.15M | -21.46M | 0 | -0.4675 |
DWLD
Davis Select Worldwide ETF
|
47.39 | 0 | 0 | 0 | 0 | 0.00 |
QQQE
Direxion NASDAQ-100 Equal Weigh
|
120.75 | 0 | 0 | 0 | 0 | 0.00 |
Pharmacyte Biotech Inc Borsa (PMCB) Ultime notizie
PMCB Q1 2026 Earnings: Clinical-Stage Biotech Posts -$0.09 EPS with No RevenueSegment Revenue Breakdown - vinanet.vn
PharmaCyte Biotech (PMCB) Climbs to $0.55 as Micro-Cap Biotech Holds Key SupportFundamentals - dars.gov.et
PharmaCyte Biotech Inc (PMCB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PharmaCyte Biotech Inc (PMCB) Stock News Today - TradingKey
PharmaCyte Biotech (PMCB) Holds Near $0.59 as Shares Dip 0.71%Change of Character - vinanet.vn
PharmaCyte Biotech (PMCB) Q1 2026 Earnings: Narrowing Loss Amid Clinical ProgressHealthcare Earnings Report - dars.gov.et
PharmaCyte Biotech, Inc. FY 2026: Revenue $0 Net income ($23.21M), EPS ($2.77) — 10-K Summary - TradingView
PharmaCyte Biotech Inc (PMCB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PharmaCyte Biotech Inc (PMCB) Institutional Confidence - TradingKey
PharmaCyte Biotech Inc (PMCB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PharmaCyte Biotech Inc (PMCB) Balance Sheet - TradingKey
PharmaCyte Biotech Inc (PMCB) Cash Flow - TradingKey
PharmaCyte Biotech Inc (PMCB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
PMCB|PharmaCyte Biotech Inc|Price:0.600|Chg%:-0.005 - TradingKey
PharmaCyte Biotech Inc (PMCB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PharmaCyte Biotech Inc (PMCB) Valuation: PE, PB & Fair Value Analysis - TradingKey
PharmaCyte Biotech Inc (PMCB) Income Statement - TradingKey
PMCB|PharmaCyte Biotech Inc|Price:0.576|Chg%:-0.024 - tradingkey.com
PMCB|PharmaCyte Biotech Inc|Price:0.611|Chg%:+0.035 - TradingKey
PharmaCyte Biotech (PMCB) Holds Near $0.57 Support Amid Minimal Price MovementSMA Signal - vinanet.vn
PharmaCyte Biotech Inc. (PMCB) Q1 2026 Earnings: Revenue-less Biotech Posts Net Loss; Stock SlipsEarnings Miss Alert - dars.gov.et
PharmaCyte Biotech, Inc. Revenue Breakdown – NASDAQ:PMCB - TradingView
PharmaCyte Biotech Inc (PMCB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PharmaCyte Biotech (PMCB) Edges Lower Near Support; Key Levels in FocusLong Short Pair - vinanet.vn
PMCB Q1 2026 Earnings: Continued Development Costs Weigh on Results, No Revenue ReportedEarnings Season Outlook - vinanet.vn
PharmaCyte Biotech (PMCB) Slips 4% as Stock Tests Key Support Near $0.60High Dividend Factor - vinanet.vn
PharmaCyte Biotech | 4: Statement of changes in beneficial ownership of securities-Director SCHECHTER JONATHAN - Moomoo
PharmaCyte Biotech (PMCB) Faces Near-Term Pressure, Testing Key Support at $0.60Tick Index - vinanet.vn
[Form 4/A] PharmaCyte Biotech, Inc. Amended Insider Trading Activity - Stock Titan
PharmaCyte Biotech (PMCB) cancels erroneous stock option grant - Stock Titan
PharmaCyte Biotech (PMCB) amends Form 4 to cancel option grant - Stock Titan
PharmaCyte Biotech (PMCB) director corrects erroneous, cancelled option grant - Stock Titan
PharmaCyte Biotech (PMCB) Slides 6.6% as Biotech Selling Pressure PersistsDebt Free Companies - dars.gov.et
PharmaCyte Biotech (PMCB) Slides 1.4% Near Key Support Level at $0.66Adaptive Moving Average - dars.gov.et
PharmaCyte Biotech (PMCB) Holds Near Support as Modest Decline Tests Trader ConvictionGap Down Bounce Plays - dars.gov.et
PMCB Q1 2026 Earnings: Losses Narrow as Biotech Advances Pipeline Amid Positive Market SentimentROA Comparison - Bölüm Sonu Canavarı
PharmaCyte Biotech | SCHEDULE 13G: Others - Moomoo
PMCB Q1 2026 Earnings: Loss Per Share of $0.09 as Clinical Pipeline AdvancesEarnings Quality Score - po-news-eg.net
PharmaCyte Biotech | DEF 14A: Definitive information statements - Moomoo
PharmaCyte Biotech Inc. (PMCB) Q1 2026 Earnings: Continued Pre‑Revenue Losses as Pipeline Development Drives Net LossEstimate Accuracy - dars.gov.et
PMCB Q1 2026 Earnings: Pre-Revenue Biotech Reports Slight Loss, Shares RiseEarnings Call Highlights - dars.gov.et
Price to book forward of PharmaCyte Biotech, Inc. – NASDAQ:PMCB - TradingView
Price to sales forward of PharmaCyte Biotech, Inc. – NASDAQ:PMCB - TradingView
Price to earnings forward of PharmaCyte Biotech, Inc. – NASDAQ:PMCB - TradingView
Enterprise value to EBITDA forward of PharmaCyte Biotech, Inc. – NASDAQ:PMCB - TradingView
Enterprise value to revenue forward of PharmaCyte Biotech, Inc. – NASDAQ:PMCB - TradingView
PharmaCyte Biotech Inc (PMCB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
PMCB Q1 2026 Earnings: Reported Loss of -$0.09 Per Share as Stock DeclinesAnalyst Consensus Shift - dars.gov.et
PMCB Q1 2026 Earnings: Pre-Revenue Biotech Reports Net Loss, Shares Slide 8%Strong Earnings Momentum - dars.gov.et
PharmaCyte Biotech (PMCB) Holds Steady at $0.7: Consolidation Near Key SupportVolume Profile - newsline.com
PMCB Q1 2026 Earnings: Modest Loss Reported Amid Early-Stage DevelopmentEarnings Surprise Report - dars.gov.et
Pharmacyte Biotech Inc Azioni (PMCB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Pharmacyte Biotech Inc Azioni (PMCB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Silverman Joshua | CEO and President |
Jan 06 '26 |
Buy |
0.79 |
30,000 |
23,667 |
376,250 |
| Silverman Joshua | CEO and President |
Jan 05 '26 |
Buy |
0.78 |
30,000 |
23,493 |
346,250 |
| SCHECHTER JONATHAN | Director |
Jan 07 '26 |
Buy |
0.84 |
20,000 |
16,872 |
192,500 |
| SCHECHTER JONATHAN | Director |
Jan 06 '26 |
Buy |
0.79 |
20,000 |
15,808 |
172,500 |
| SCHECHTER JONATHAN | Director |
Jan 05 '26 |
Buy |
0.78 |
20,000 |
15,552 |
152,500 |
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):